The Revogene® instrument is intended for in vitro diagnostic (IVD) use in performing nucleic acid testing of specific IVD assays in clinical laboratories. The revogene is capable of automated lysis and dilution of samples originating from various clinical specimen types. Revogene® performs automated amplification and detection of target nucleic acid sequences by fluorescence based real time PCR.


Revogene® Gerät und Probenverarbeitung


  • Closed cartridge called PIE (no contamination)
  • Robust and reliable internal control integrated
  • Turnaround time (TAT) under 70 minutes
    • „Early-calls“ at 40 minutes possible
  • Minimal waste due to small size of the PIEs
  • Compatible with many sample types (direct specimen without pre-treatment)
  • User-friendly, intuitive touch-screen software
  • Bidirectional communication for fully integration in the LIS
  • Small footprint (ca. A4-Paper)
  • Integrated barcode reader
  • Minimal maintenance requirements (yearly calibration)
  • Validated cuf-off based decision algorithm
  • Storage of the reagents at room temperature


Current assays:

  • C. difficile (Toxin B; tcdB-Gene)
  • Carba C (Carbapenem-resistance; Genes: NDM, KPC, OXA-48-like, IMP, VIM)
  • Strep A (Streptococcus pyogenes; Group A β-hemolytic Streptococcus, GAS)
  • GBS DS (Streptococci of group B)


Future assays:

  • Bacterial GI-Smart Panel (Campylobacter spp., Enterotoxigenic E. coli (ETEC) LT/ST, Salmonella spp., Shiga-like toxin producing E. coli
    (STEC) stx1/stx2 (incl. identification of E. coli 0157), Shigella spp/Enteroinvasive E. coli (EIEC), Vibrio spp., Yersinia enterocolitica)
  • H. pylori / Resistance (Cla/levo)
  • Respiratory-Smart Panel (Flu A, Flu B, RSV, hMPV, Parainfluenza 1-4, Adenovirus)
  • SARS-CoV-2

Datasheet download